Providing leading edge diagnostic solutions in oncology

AccuGenomics provides gene expression tests that accurately diagnose, monitor and inform cancer treatment. AccuGenomics' technologies generate the most comprehensive test results which ensure confidence in clinical decisions and provide credible and reliable gene expression data to the medical community.

Breaking News:

StarSeq Presented at FDA Workshop on Next Generation Sequencing-Based Oncology Panels

Wilmington, NC February 2016.  Dr. James Willey presents AccuGenomics NGS quality control method at the Public Workshop – Next Generation Sequencing-Based Oncology Panels. The FDA held a public meeting to gather input on strategies for establishing performance characteristics for NGS-based oncology panels for rare variants across tumor types.  This need has become important as more…

Release of lung cancer risk test trial details and establishment of biospecimen repository.

A January 22, 2016 BioMed Central Pulmonary Medicine article details the trial design and establishment of a biospecimen repository necessary for the clinical validation of the AccuGenomics’ Lung Cancer Risk Test (LCRT).  The LCRT is a 15-gene molecular test that could reduce overall lung cancer screening by demonstrating a person’s genetic propensity towards lung cancer,…

AccuGenomics partners with Green Hills Ventures

AccuGenomics releases video describing their partnership with Green Hills Ventures to raise series A capital to accelerate the clinical validation of their proprietary AccuKit BCR-ABL and Lung Cancer Diagnostic test.  

Progress in Efforts to Develop AccuKit for Monitoring of BCR-ABL Treatment

AccuGenomics develops standardized molecular testing kits that support the personalized medicine market.  On March 17, 2015, the company was awarded a United States patent 8,981,068, which has critical claims for their standardized molecular testing platform.  “We are very excited about the issuance of this patent”, says Tom Morrison, Chief Science Officer of AccuGenomics.  “The patent’s…